World's Best Scientists 2026 revealed!
Malcolm David Mason

Malcolm David Mason

D-Index & Metrics

Medicine

D-Index
106
Citations
62083
World Ranking
6378
National Ranking
620

Malcolm David Mason publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Malcolm David Mason sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 498 publications — 58th percentile

58% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Malcolm David Mason D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Malcolm David Mason sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 106 D-Index — 69th percentile

69% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Malcolm David Mason is affiliated with Cardiff University in the United Kingdom. Their research primarily spans the field of Medicine, with a strong focus on subfields such as Pulmonary and Respiratory Medicine, Oncology, Surgery, Radiology, Nuclear Medicine and Imaging, and Internal Medicine.

Their work covers multiple topics, prominently including Prostate Cancer Treatment and Research, Prostate Cancer Diagnosis and Treatment, and Bladder and Urothelial Cancer Treatments. Additional research interests involve Radiopharmaceutical Chemistry and Applications, Venous Thromboembolism Diagnosis and Management, Hormonal and Reproductive Studies, and Colorectal Cancer Screening and Detection.

Malcolm David Mason has coauthored publications with several frequent collaborators. These include:

  • Silke Gillessen
  • Nicolas Mottet
  • Philip Cornford
  • Thomas Wiegel
  • Thomas Van den Broeck

The scientist has contributed articles to various publication venues. The most common among these are:

  • European Urology
  • The Lancet Oncology
  • British Journal of Urology
  • European Urology Focus
  • British Journal of Cancer

Some of their recent papers include:

  • EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent, 2020, European Urology
  • EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer, 2020, European Urology
  • Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer, 2023, New England Journal of Medicine
  • Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review, 2020, European Urology
  • Association of Bone Metastatic Burden With Survival Benefit From Prostate Radiotherapy in Patients With Newly Diagnosed Metastatic Prostate Cancer, 2021, JAMA Oncology

Best Publications

  • EAU–ESTRO–SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent

    Nicolas Mottet;Joaquim Bellmunt;Michel Bolla;Erik Briers

  • 10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer

    Freddie C. Hamdy;Jenny L. Donovan;J. Athene Lane;Malcolm Mason

  • EAU Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent—Update 2013

    Axel Heidenreich;Patrick J. Bastian;Joaquim Bellmunt;Michel Bolla

  • EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer—2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent

    Nicolas Mottet;Roderick C.N. van den Bergh;Erik Briers;Thomas Van den Broeck

  • EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease.

    Axel Heidenreich;Joaquim Bellmunt;Michel Bolla;Steven Joniau

  • Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy

    Nicholas D. James;Johann S. de Bono;Melissa R. Spears;Noel W. Clarke

  • Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial

    Nicholas D. James;Nicholas D. James;Matthew R. Sydes;Noel W. Clarke;Malcolm David Mason

  • EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer

    Philip Cornford;Joaquim Bellmunt;Michel Bolla;Erik Briers

  • EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer ☆

    Nicolas Mottet;Joaquim Bellmunt;Michel Bolla;Steven Joniau

  • 前立腺癌のEAUガイドライン。パート1:臨床的限局性疾患のスクリーニング,診断および治療

    A Heidenreich;J Bellmunt;M Bolla;S Joniau

  • Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer

    Donovan Jl;Hamdy Fc;Lane Ja;Mason M

  • Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial.

    Christopher C Parker;Nicholas D James;Christopher D Brawley;Noel W Clarke

  • Cancer exosomes trigger fibroblast to myofibroblast differentiation

    Jason P. Webber;Robert Steadman;Malcolm David Mason;Zsuzsanna Tabi

  • EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer

    Philip Cornford;Roderick C.N. van den Bergh;Erik Briers;Thomas Van den Broeck

  • European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer: A Report of the Second Meeting of the European Germ Cell Cancer Consensus group (EGCCCG): Part I

    Susanne Krege;Jörg Beyer;Rainer Souchon;Peter Albers

  • Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial

    Padraig Warde;Malcolm David Mason;Keyue Ding;Peter Kirkbride

  • European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG)

    H. J. Schmoll;R. Souchon;S. Krege;P. Albers

  • Human Tumor-Derived Exosomes Down-Modulate NKG2D Expression

    Aled Clayton;J. Paul Mitchell;Jacquelyn Court;Seamus Linnane

  • Guía de la EAU sobre el cáncer de próstata: Parte II: tratamiento del cáncer de próstata avanzado, recidivante y resistente a la castración

    N. Mottet;Joaquim Bellmunt;M. Bolla;S. Joniau

  • EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer - Guía de la EAU sobre el cáncer de próstata. Parte II: tratamiento del cáncer de próstata avanzado, recidivante y resistente a la castración

    N. Mottet;J. Bellmunt;M. Bolla;S. Joniau

Frequent Co-Authors

Wen Guo Jiang
Wen Guo Jiang Cardiff University
Matthew R. Sydes
Matthew R. Sydes University College London
Nicholas D. James
Nicholas D. James Institute of Cancer Research
David P. Dearnaley
David P. Dearnaley Institute of Cancer Research
Noel W. Clarke
Noel W. Clarke University of Salford
Silke Gillessen
Silke Gillessen Universita della Svizzera Italiana
Mahesh K. B. Parmar
Mahesh K. B. Parmar University College London
Chris Parker
Chris Parker Institute of Cancer Research
Timothy J Wilt
Timothy J Wilt University of Minnesota
David E. Neal
David E. Neal University of Cambridge

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students interested in alternative or supplementary pathways to a career in healthcare, there are numerous flexible and affordable online options available. One popular route is pursuing affordable nursing programs online, which allow students to learn at their own pace while preparing for rewarding roles in patient care.

Registered nurses seeking higher credentials can explore the cheapest bsn programs to enhance their qualifications and job prospects. For those aiming for leadership, nurse practitioner, or teaching positions, the cheapest dnp programs offer an efficient way to earn a terminal degree in nursing without breaking the bank.

Individuals with non-nursing backgrounds who are considering a career change can benefit from online msn programs for non nurses, bridging the transition into advanced nursing roles. These pathways provide flexibility, affordability, and a variety of specializations, making healthcare careers accessible to more people than ever before.

Best Scientists Citing Malcolm David Mason

Trending Scientists

Recently Published Articles